High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial (Q37507802)

20 August 2017

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial (English)

1 reference

20 August 2017

0 references

1 reference

1 reference

Norbert Heinrich

2

0 references

Stephen H Gillespie

object named as

Stephen H Gillespie

27

0 references

Salome Charalambous

13

object named as

Salome Charalambous

1 reference

20 August 2017

16

Stellah G Mpagama

1 reference

20 August 2017

19

Klaus Reither

1 reference

20 August 2017

29

Michael Hoelscher

1 reference

20 August 2017

9

Ian Sanne

1 reference

20 August 2017

7

Gibson S Kibiki

1 reference

20 August 2017

1

Martin J Boeree

1 reference

20 August 2017

Rob Aarnoutse

3

1 reference

20 August 2017

Andreas H Diacon

4

1 reference

20 August 2017

Rodney Dawson

5

1 reference

20 August 2017

Sunita Rehal

6

1 reference

20 August 2017

Gavin Churchyard

8

1 reference

20 August 2017

Nyanda E Ntinginya

10

1 reference

20 August 2017

Lilian T Minja

11

1 reference

20 August 2017

Robert D Hunt

12

1 reference

20 August 2017

Madeleine Hanekom

14

1 reference

20 August 2017

Hadija H Semvua

15

1 reference

20 August 2017

Christina Manyama

17

1 reference

20 August 2017

Bariki Mtafya

18

1 reference

20 August 2017

Robert S Wallis

20

1 reference

20 August 2017

Amour Venter

21

1 reference

20 August 2017

Kim Narunsky

22

1 reference

20 August 2017

Anka Mekota

23

1 reference

20 August 2017

Sonja Henne

24

1 reference

20 August 2017

Angela Colbers

25

1 reference

20 August 2017

Georgette Plemper van Balen

26

1 reference

20 August 2017

Patrick P J Phillips

28

1 reference

20 August 2017

PanACEA consortium

30

1 reference

20 August 2017

26 October 2016

1 reference

Lancet Infectious Diseases

20 August 2017

1 reference

20 August 2017

17

1 reference

20 August 2017

1

1 reference

20 August 2017

39-49

1 reference

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

The association between sterilizing activity and drug distribution into tuberculosis lesions

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Clinical Pharmacokinetics of Rifampicin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5159618

10.1016/S1473-3099(16)30274-2

2 October 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

28100438

1 reference